This investigation provides support for IBI315 as a promising bispecific antibody‐based immunotherapeutic strategy in preclinical evaluations, thereby broadening the therapeutic landscape for Her2‐positive gastric cancer patients. This evidence concerns the gene ERBB2 and gastric cancer.